Work

Response to “Erlotinib and Gastric Acid–Reducing Agents: A Combination to Avoid or to Support?”

Year: 2014

Type: letter

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1038/clpt.2014.192

Authors: L Zhang, S C Lee, H Zhao, F Wu, L Zhang

Institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research, Oak Ridge Institute for Science and Education

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2093068463

Cites: 4

Cited by: 1

Related to: 10